Showing 3831-3840 of 8892 results for "".
- FDA Accepts Arcutis Biotherapeutics’ NDA for Roflumilast Cream for Adults and Adolescents with Plaque Psoriasishttps://practicaldermatology.com/news/fda-accepts-arcutis-biotherapeutics-nda-for-roflumilast-cream-for-adults-and-adolescents-with-plaque-psoriasis/2461018/The FDA accepted Arcutis Biotherapeutics’ new drug application (NDA) for roflumilast cream for the treatment of psoriasis in adults and adolescents. The FDA assigned the application a Prescription Drug User Fee Act (PDUFA) target action date of July 29, 2022. “With the FDA c
- Study: Brepocitinib Reduces Inflammatory Markers in Cicatricial Alopeciahttps://practicaldermatology.com/news/study-brepocitinib-reduces-inflammatory-markers-in-cicatricial-alopecia/2471712/A recent phase 2a clinical trial showed brepocitinib was associated with a significant reduction in C-C motif chemokine ligand 5 (CCL5) expression and improved clinical severity scores in patients with cicatricial alopecia (CA).
- Valeant Appoints New Chief Quality Officerhttps://practicaldermatology.com/news/valeant-appoints-new-chief-quality-officer/2458416/Valeant Pharmaceuticals International, Inc. appointed Louis W. Yu, PhD to the newly created position of Chief Quality Officer, Global Quality, effective October 3, 2016. Dr. Yu reports to Joseph C. Papa, C
- Valeant is Becoming Bausch Health Companies, Inc.https://practicaldermatology.com/news/valeant-is-becoming-bausch-health-companies-inc/2457770/Bausch Health Companies, Inc. will become the new name of Valeant Pharmaceuticals International, Inc., effective in July 2018. Based on th
- Arcutis, Huadong Announce Strategic Collab and Licensing Agreement for Topical Roflumilast in Greater China and Southeast Asiahttps://practicaldermatology.com/news/arcutis-huadong-announce-strategic-collab-and-licensing-agreement-for-topical-roflumilast-in-greater-china-and-southeast-asia/2461921/Arcutis Biotherapeutics, Inc. and Hangzhou Zhongmei Huadong Pharmaceutical Co. have entered into a strategic c
- DermTech Appoints Two New Board Membershttps://practicaldermatology.com/news/dermtech-appoints-two-new-board-members/2461272/DermTech, Inc. appointed Kirk D. Malloy, Ph.D. and Mark C. Capone, M.S. to the Company’s board of directors, effective July 18,2022. These appointments expand DermTech’s board of directors to eight members. “We are excited to welco
- Consensus: Straight-Line Vector Planning Produces Best Silhouette InstaLift Resultshttps://practicaldermatology.com/news/consensus-straight-line-vector-planning-produces-best-silhouette-instalift-results/2457668/Straight-line vector planning produces the ideal lifting effect and sets the stage for maximum collagen regeneration with the Silhouette InstaLift, according to a study in the July 2018 issue of Journal of Drugs in Dermat
- PAH after Cryolipolysis May Not Be So 'Rare'https://practicaldermatology.com/news/pah-after-cryolipolysis-may-not-be-so-rare/2457707/Paradoxical adipose hyperplasia (PAH) after cryolipolysis may be more common than previously thought according to a paper in the July issue of Plastic and Reconstructive Surgery®. While PAH can be treated successfully
- Dermatologist Warns of "Lime Disease"—Phytophotodermatosis—In Conjunction with National Tequila Dayhttps://practicaldermatology.com/news/dermatologist-warns-of-lime-diseasephytophotodermatosisin-conjunction-with-national-tequila-day/2458907/Margaritas may be the choice cocktail on July 24 to celebrate National Tequila Day, but Dr. Howard Steinman, a dermatologist with DermOne Dermatology Centers, has a sour warning: Sipping citrus fruit
- Amgen, Pfizer Will No Longer Co-Market Enbrelhttps://practicaldermatology.com/news/20120419-amgen_pfizer_will_no_longer_co-market_enbrel/2459819/Amgen and Pfizer will end co-promotion of Enbrel (etanercept) in North America this summer, the companies tell the Wall Street Journal. Amgen will assume full marketing responsibilities in the US, effective July 23.